TWI633115B - 加成糖鏈之多胜肽及含有該多胜肽之醫藥組成物 - Google Patents

加成糖鏈之多胜肽及含有該多胜肽之醫藥組成物 Download PDF

Info

Publication number
TWI633115B
TWI633115B TW101136177A TW101136177A TWI633115B TW I633115 B TWI633115 B TW I633115B TW 101136177 A TW101136177 A TW 101136177A TW 101136177 A TW101136177 A TW 101136177A TW I633115 B TWI633115 B TW I633115B
Authority
TW
Taiwan
Prior art keywords
sugar chain
peptide
added
fmoc
amino acid
Prior art date
Application number
TW101136177A
Other languages
English (en)
Chinese (zh)
Other versions
TW201321404A (zh
Inventor
土反本泉
深江一博
手塚克成
田鶴圭亮
前田政敏
梶原康宏
滋濟孝
Original Assignee
日商糖鎖工學研究所股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商糖鎖工學研究所股份有限公司 filed Critical 日商糖鎖工學研究所股份有限公司
Publication of TW201321404A publication Critical patent/TW201321404A/zh
Application granted granted Critical
Publication of TWI633115B publication Critical patent/TWI633115B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW101136177A 2011-10-01 2012-10-01 加成糖鏈之多胜肽及含有該多胜肽之醫藥組成物 TWI633115B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011218793 2011-10-01
JP2011-218793 2011-10-01

Publications (2)

Publication Number Publication Date
TW201321404A TW201321404A (zh) 2013-06-01
TWI633115B true TWI633115B (zh) 2018-08-21

Family

ID=47995870

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101136177A TWI633115B (zh) 2011-10-01 2012-10-01 加成糖鏈之多胜肽及含有該多胜肽之醫藥組成物

Country Status (16)

Country Link
US (1) US10358470B2 (enExample)
EP (1) EP2762489B1 (enExample)
JP (1) JP6153470B2 (enExample)
KR (1) KR101979045B1 (enExample)
CN (2) CN104080803B (enExample)
AU (1) AU2012317325B2 (enExample)
BR (1) BR112014007766B1 (enExample)
CA (1) CA2850469C (enExample)
DK (1) DK2762489T3 (enExample)
IN (1) IN2014CN02982A (enExample)
MY (1) MY168902A (enExample)
PH (1) PH12014500694B1 (enExample)
RU (1) RU2636456C2 (enExample)
SG (2) SG11201401071YA (enExample)
TW (1) TWI633115B (enExample)
WO (1) WO2013047846A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101979045B1 (ko) 2011-10-01 2019-05-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물
DK2982686T3 (en) 2013-03-29 2018-10-08 Glytech Inc POLYPEPTIDE WITH SIALYLED SUGAR CHAIN CONNECTED
CN114685645B (zh) * 2020-12-30 2025-03-21 深圳翰宇药业股份有限公司 一种索玛鲁肽的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020033A1 (en) * 2000-09-08 2002-03-14 Gryphon Therapeutics, Inc. Polymer-modified synthetic proteins
US20080003202A1 (en) * 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237019A3 (en) * 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
ES2218806T3 (es) 1997-01-16 2004-11-16 Neose Technologies, Inc. Sialilacion practica in vitro de glicoproteinas recombinantes.
DE19717864C2 (de) 1997-04-23 2001-05-17 Fraunhofer Ges Forschung Humanes rekombinantes Interferon-beta, Verfahren zu seiner Herstellung und seine Verwendung
BR9910023A (pt) * 1998-04-28 2000-12-26 Applied Research Systems Conjugados de poliol-ifn-beta
EE05111B1 (et) * 1998-10-16 2008-12-15 Biogen, Incorporated Interferoon-beetaga sulandatud valgud ja nende kasutamine
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
DE60037978T2 (de) * 1999-12-08 2008-05-21 Amgen Inc., Thousand Oaks Interferon ähnliche moleküle, und deren verwendungen
US7795002B2 (en) * 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
JP2004534523A (ja) 2001-02-27 2004-11-18 マキシゲン・エイピーエス 新規なインターフェロンβ様分子
CA2441095A1 (en) 2001-03-15 2002-09-26 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified interferon beta with reduced immunogenicity
US7226903B2 (en) * 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
EP2305312B1 (en) * 2001-10-10 2015-03-04 ratiopharm GmbH Remodelling and glycoconjugation of follicle-stimulating hormone (FSH)
CA2469487A1 (en) 2001-12-11 2003-07-03 Aventis Pasteur Mutated hiv tat
MXPA04008798A (es) 2002-03-12 2004-11-26 Maxygen Aps Moleculas semejantes a interferon beta para el tratamiento de evento cerebrovascular.
US7943763B2 (en) 2002-07-05 2011-05-17 Otsuka Chemical Holdings Co., Ltd. Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides
AU2003254641A1 (en) 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
PL377612A1 (pl) * 2002-09-27 2006-02-06 Biogen Idec Ma Inc. Terapie przewlekłej zapalnej polineuropatii demielinizacyjnej z użyciem interferonu-ß
AU2003277088A1 (en) 2002-10-01 2004-04-23 Xencor, Inc Interferon variants with improved properties
AU2003292792A1 (en) 2002-12-26 2004-07-22 Kajihara, Yasuhiro Sugar-chain asparagine derivatives and processes for the preparation thereof
EP1666496B1 (en) 2003-08-25 2014-03-12 Toray Industries, Inc. Interferon-beta composite
JP2007526317A (ja) 2004-03-01 2007-09-13 エンゾン ファーマスーティカルズ インコーポレイテッド インターフェロン−ベータ・ポリマー結合体
EP1789074A4 (en) 2004-08-09 2009-08-12 Alios Biopharma Inc PROTEASE-RESISTANT HYPERGLYCOSYL SYNTHETIC POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME
RU2392963C2 (ru) * 2004-08-09 2010-06-27 Элиоз Байофарма, Инк. Синтетические варианты гипергликозилированного протеазо-резистентного полипептида, пероральные композиции и способы применения таких вариантов
KR100781666B1 (ko) 2004-11-02 2007-12-03 신영기 인간 인터페론-베타 변이체
SG155183A1 (en) * 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
TWI423821B (zh) 2007-06-19 2014-01-21 Glucose-containing glucagon-like peptide-1 peptide
AU2008283317B2 (en) 2007-07-31 2012-08-02 Glytech, Inc. Method for producing peptide
JP2009242372A (ja) 2008-03-11 2009-10-22 Yokohama City Univ 均一な糖鎖構造を有するエリスロポエチン誘導体
JP5604297B2 (ja) 2008-06-17 2014-10-08 株式会社糖鎖工学研究所 糖鎖付加ｇｌｐ−１ペプチド
CA2733362C (en) 2008-08-08 2016-10-18 Universiteit Gent Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof
KR20110067097A (ko) * 2008-08-19 2011-06-21 오츠카 가가쿠 가부시키가이샤 당단백질의 제조방법 및 스크리닝 방법
WO2012051615A1 (en) 2010-10-15 2012-04-19 Transgenrx, Inc. Novel vectors for production of glycosylated interferon
SG193377A1 (en) 2011-03-10 2013-10-30 Glytech Inc Method for producing glycopeptide having sialyl sugar chain, sialyl sugar chain-added amino acid derivative to be used in same, and glycopeptide
ES2774284T3 (es) 2011-06-29 2020-07-20 Kyowa Kirin Co Ltd Método para purificar antitrombina
KR101979045B1 (ko) 2011-10-01 2019-05-15 가부시키가이샤 도우사 고가쿠 겐큐쇼 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020033A1 (en) * 2000-09-08 2002-03-14 Gryphon Therapeutics, Inc. Polymer-modified synthetic proteins
US20080003202A1 (en) * 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides

Also Published As

Publication number Publication date
EP2762489A9 (en) 2015-02-11
SG10201602076QA (en) 2016-04-28
CA2850469C (en) 2020-07-07
CN104080803A (zh) 2014-10-01
US10358470B2 (en) 2019-07-23
RU2014116550A (ru) 2015-10-27
KR101979045B1 (ko) 2019-05-15
RU2636456C2 (ru) 2017-11-23
MY168902A (en) 2018-12-04
BR112014007766A2 (pt) 2017-04-04
DK2762489T3 (en) 2018-07-02
CN104080803B (zh) 2020-08-04
JP6153470B2 (ja) 2017-06-28
CN109134642A (zh) 2019-01-04
AU2012317325B2 (en) 2016-10-06
EP2762489B1 (en) 2018-03-28
EP2762489A1 (en) 2014-08-06
US20140369964A1 (en) 2014-12-18
EP2762489A4 (en) 2015-05-06
IN2014CN02982A (enExample) 2015-07-03
SG11201401071YA (en) 2014-08-28
CA2850469A1 (en) 2013-04-04
TW201321404A (zh) 2013-06-01
KR20140095051A (ko) 2014-07-31
PH12014500694B1 (en) 2020-01-31
BR112014007766B1 (pt) 2022-05-10
WO2013047846A1 (ja) 2013-04-04
JPWO2013047846A1 (ja) 2015-03-30
PH12014500694A1 (en) 2014-05-12
AU2012317325A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
TWI423821B (zh) Glucose-containing glucagon-like peptide-1 peptide
CN102083854A (zh) 附加了糖链的glp-1肽
CN114269775A (zh) 肠促胰岛素类似物的制备方法
CN104936613B (zh) 糖链加成连接子、含有糖链加成连接子与生理活性物质的化合物或其盐、以及其制造方法
JPWO2012121206A1 (ja) シアリル糖鎖を有する糖ペプチドの製造方法、当該製造方法に使用するシアリル糖鎖付加アミノ酸誘導体、及び当該糖ペプチド
TWI633115B (zh) 加成糖鏈之多胜肽及含有該多胜肽之醫藥組成物
EP2982686B1 (en) Polypeptide having sialylated sugar chains attached thereto
WO2011007747A1 (ja) 糖鎖付加ａｉｌｉｍ細胞外ドメイン及びその製造方法

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees